Clinical trialsCompany release

Viking Therapeutics starts oral VK2735 Phase 3 SUNRISE programme and reports $960m cash

🇺🇸 Viking Therapeutics, Inc. (VKTX) · Wed 28 Oct 2026

The obesity drug developer launched Phase 3 trials of oral VK2735 in obesity and type 2 diabetes, while its subcutaneous VANQUISH studies remain on track to complete in 2027.

Viking Therapeutics reported third-quarter 2026 results on 28 October alongside a pipeline update. The main development was the start of SUNRISE, a Phase 3 programme testing oral VK2735 in obesity and in type 2 diabetes.

The company said its subcutaneous VK2735 Phase 3 trials, known as VANQUISH, are on track to finish in 2027. The source summary does not give further detail on enrolment, endpoints or design for either programme.

Viking also reported positive results from a maintenance dosing study of VK2735 and has begun Part 2 of that study. The summary available does not set out the data, the dosing regimens tested or what Part 2 will assess.

On finances, the company ended the quarter with $960 million in cash. No further financial figures were available in the material reviewed.

What it means for your team

  • Viking now has both oral and subcutaneous VK2735 in Phase 3, so regulatory teams tracking the incretin-based obesity field should watch for separate development paths and timelines for each formulation.
  • The 2027 completion target for VANQUISH sets an expected window for data that could eventually support regulatory submissions, though no filing plans were stated.
  • Maintenance dosing data may become relevant to market-access discussions on long-term treatment, but Part 2 of the study is only beginning and full results were not provided.
  • The reported $960 million cash position is a company-reported figure; the source gave no detail on how it relates to trial or commercial plans.

Company's press release (SEC filing): Viking Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Viking Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →